11/25
09:06 am
vor
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
11/14
08:09 am
vor
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
11/13
07:23 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/10
09:56 pm
vor
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
High
Report
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
11/10
04:01 pm
vor
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
High
Report
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
11/8
11:45 am
vor
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Low
Report
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
11/7
08:00 am
vor
Vor Bio to Participate in Upcoming Investor Conferences
Low
Report
Vor Bio to Participate in Upcoming Investor Conferences
11/3
08:00 am
vor
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Medium
Report
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
10/31
04:30 pm
vor
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/29
01:47 pm
vor
Vor Biopharma (NASDAQ:VOR) had its price target raised by analysts at HC Wainwright from $3.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Vor Biopharma (NASDAQ:VOR) had its price target raised by analysts at HC Wainwright from $3.00 to $52.00. They now have a "buy" rating on the stock.
10/29
11:01 am
vor
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Low
Report
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
10/22
04:30 pm
vor
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
Medium
Report
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
10/17
08:00 am
vor
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
Low
Report
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
10/16
08:00 am
vor
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
Medium
Report
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
10/16
06:39 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
10/15
08:12 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $64.00 price target on the stock, up previously from $20.00.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $64.00 price target on the stock, up previously from $20.00.
10/15
07:11 am
vor
Vor Biopharma (NASDAQ:VOR) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
10/14
08:00 am
vor
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
Medium
Report
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
10/3
04:53 pm
vor
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/3
04:01 pm
vor
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/29
07:00 am
vor
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
High
Report
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
9/25
11:51 am
vor
Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise [Seeking Alpha]
Low
Report
Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise [Seeking Alpha]
9/24
08:06 am
vor
Vor Biopharma (NYSE:VOR) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock.
Medium
Report
Vor Biopharma (NYSE:VOR) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock.
9/23
08:00 am
vor
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
High
Report
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
9/17
04:15 pm
vor
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
Neutral
Report
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM